Is bipolar disorder neuroprogressive? Insights into brain structure, cognition, and biomarkers from longitudinal investigations

Mikael Landén

Is bipolar disorder neuroprogressive? Neurobiological mechanisms of compulsive alcohol use

Markus Heilig

The COMB-study; a multicenter RCT on the effects of varenicline and bupropion in alcohol use disorder.

Andrea de Bejczy, Bo Söderpalm, Johan Franck, Anders Håkansson, Markus Heilig

Sodium oxybate: a substitution therapy for alcohol use disorder?

Julien Guiraud

Exploring the cerebrospinal fluid proteome in bipolar disorder

Andreas Göteson, Lina Jonsson, Aurimantas Pelanis, Erik Pålsson, Henrik Zetterberg, Kaj Blennow, Jessica Holmén-Larsson, Johan Gobom, Mikael Landén

In vivo evidence that interactions between dopaminergic and serotonergic receptors underlie the complex impact of the dopamine stabiliser (-) OSU6162 on psychomotor activity

Daniela Atanasovski, Elias Eriksson

Integrative analysis multi-omics analysis of proteomics and metabolomics data of Karolinska Schizophrenia Project (KaSP)

Feride Ayten Eren, Humza Haroon, Sophie Erhardt, Doo-Sup Choi

A Macrobiotic Approach to Ameliorate "Chemo-brain" and Chemotherapy-induced Sickness

Eleonora Genovese, Bradley Whitehead, Gregers Wegener, Peter Nejsum, Cecilie Bay-Richter

Molecular Interaction of Antidepressants with Estrogen Receptor Alpha

Shokouh Arjmand, Rachele Rossi, Christian B. Vægter, Steffen Sinning, Heidi K. Müller, Birgit Schiøtt, Claudia Cecchi, Jayashree Sahana, Anne M. Landau, Gregers Wegener, Sâmia Joca, Caroline Biojone

Selective manipulation of striatal dopamine

Klara Danielsson, Rosita Stomberg, Louise Adermark, Mia Ericson, Bo Söderpalm

New treatment options in TRD: hope or hype?

Andreas Reif

Real-world effectiveness of ADHD medications in amphetamine dependence and borderline personality disorder

Milja Hartikainen

•ADHD drug use in Iceland and hospitalization for new-onset psychosis or mania among adults

Ragna Kristín Guðbrandsdóttir, Engilbert Sigurðsson, Halldóra Jónsdóttir, Þorsteinn Ívar Albertsson, Oddur Ingimarsson

ADHD medications and long-term risk of cardiovascular diseases

Le Zhang, Lin Li, Pontus Andell, Miguel Garcia-Argibay, Patrick D. Quinn, Brian M. D’Onofrio, Isabell Brikell, Ralf Kuja-Halkola, Paul Lichtenstein, Kristina Johnell, Henrik Larsson, Zheng Chang

Novel trial designs to personalize antidepressant treatment

Daniel Lindqvist

Psilocybin as an antidepressant? Clinical effect and biological correlates

Johan Lundberg

Psychocotropic medication and the fetal brain

Lars Henning Pedersen

Treatment resistance in psychotic disorders.

Ingrid Melle, Isabel Kreis, Kristin Fjelnseth Wold

ImmunoPsychiatry – evidence from large-scale studies to detailed clinical studies

Michael Eriksen Benros

Add-on prednisolone vs. placebo in early psychotic disorders: Results of a pilot study.

Erik Johnsen

Studies of glial cells and synaptic markers in early stages of psychosis and clinical high-risk states

Simon Cervenka

Endocannabinoid dysregulation in psychotic disorders

Heikki Laurikainen, Reetta-Liina Armio, Lauri Tuominen, Anna Kirjavainen, Olof Solin, Merja Haaparanta-Solin, Raimo K R Salokangas, Jarmo Hietala